Prospective Biospecimen Collection Services
Prospective Biospecimen Collection Services.
When the sample your study needs does not exist yet, it has to be collected on purpose. That is what prospective biospecimen collection means: Sanguine designs and runs custom collections of biospecimens for research — your cohort, your tube type, your timepoints, your processing window — from IRB submission through cold-chain delivery to your bench.
Study model
Custom, protocol-driven collection
Donor network
Patients & healthy volunteers, nationwide
Draw settings
In-home mobile phlebotomy or clinical site
Delivery
Cold chain with matched de-identified data
What prospective biospecimen collection changes
Samples built to your protocol, not pulled from a freezer
Banked biospecimens answer questions that were already anticipated. A prospective biospecimen collection is designed around your protocol, so the variables that decide whether an assay is reproducible — anticoagulant, processing window, aliquot volume, donor phenotype, timepoint spacing — are yours to set instead of yours to inherit.
Banked / retrospective
- Fixed processing and annotation
- Donor no longer reachable
- Timepoints limited to what exists
- Fast and low cost
Prospective / custom
- Processing written to your SOP
- Recallable donors for repeat draws
- Longitudinal and pre/post designs
- Built for rare and narrow cohorts
The strongest analysis in the world cannot recover a variable that was never controlled at collection.Sanguine // Collection Methodology
Collection capabilities
Every collection is built from the same blocks
Every prospective biospecimen collection draws on the same core capabilities to produce biospecimens for research that are fit for purpose. What changes is how tightly each one is specified for your study.
Cohorts
Patient & healthy-donor cohorts
Recruit to your inclusion and exclusion criteria — diagnosis, treatment line, biomarker status, demographics, or matched healthy controls — from a nationwide consented donor network.
Logistics
In-home mobile phlebotomy
Draws happen where the donor is: at home, at a clinical site, or at a partner facility. Removing travel burden is what keeps hard-to-reach cohorts enrolling and returning.
Processing
Protocol-defined processing
Specify tube type, anticoagulant, volume, vein-to-processing window, aliquot scheme, cryopreservation, and shipping condition. Deviations are documented, not silently absorbed.
Data
Matched de-identified clinical data
Each specimen ships with the annotation your analysis needs — diagnosis, medications, labs, demographics, and visit context — de-identified in line with HIPAA.
Longitudinal
Recallable, repeat-draw donors
Donors can be re-contacted for additional timepoints, larger volumes, or added assays, so a study can extend without restarting recruitment.
Rare
Hard-to-source indications
Rare disease, narrow biomarker windows, treatment-naive patients, and matched pre/post-treatment sets — the collections a fixed catalog cannot answer.
Sample types
- + Whole blood
- + Serum
- + Plasma (EDTA / heparin / citrate)
- + PBMCs
- + Leukopak
- + Bone marrow
- + Synovial fluid
- + Saliva, urine, stool
- + Skin punch biopsy
Therapeutic areas
- + Oncology
- + Autoimmune & inflammation
- + Dermatology
- + Endocrine & metabolic
- + Infectious disease
- + Neurology
- + Rare disease
- + Healthy controls
How it works
How a collection runs, end to end
-
01
Protocol & feasibility
Share the target cohort, sample types, timepoints, and assays. We return a feasibility read on recruitability, volumes, and realistic timelines before anything is committed.
-
02
IRB approval
The collection protocol, consent language, and data plan go to IRB review. Nothing is drawn outside an approved protocol.
-
03
Recruitment & consent
Eligible donors are identified, screened against your criteria, and consented for research use, including recall for later timepoints.
-
04
Collection & processing
Trained phlebotomists collect on schedule; samples are processed to your SOP inside the defined window and tracked specimen by specimen.
-
05
Cold-chain delivery
Aliquots ship at the required temperature with chain-of-custody and matched clinical annotation, ready to go straight onto the bench.
Quality & compliance
Quality & compliance
- + Collections run only under an IRB-approved protocol with documented research consent.
- + Clinical data is de-identified in line with HIPAA before it reaches your team.
- + Chain of custody and processing times are recorded specimen by specimen.
- + Protocol deviations are documented and reported, not quietly normalized.
- + Donor recall permissions are captured at consent, so longitudinal designs stay compliant.
FAQ
Frequently asked questions
What is prospective biospecimen collection?
Prospective collection means samples are drawn to your protocol after your study is designed, rather than pulled from existing biobank inventory. You define donor criteria, sample types, processing, timepoints, and clinical data captured, and collection begins once the protocol is IRB-approved.
How is it different from buying banked (retrospective) samples?
Banked samples are fast and inexpensive, but fixed — you accept whatever was collected, processed, and annotated at the time. Prospective collection lets you control anticoagulant, processing window, volume, timepoints, and matched clinical data, and lets you re-contact the same donors for longitudinal follow-up draws.
Which sample types can be collected?
Whole blood, serum, plasma, PBMCs, buffy coat, bone marrow, saliva, urine, stool, tissue, and other specimen types — including matched multi-sample sets drawn at the same donor visit.
How are donors recruited and consented?
Donors are recruited from a nationwide network of patients and healthy volunteers who consent to research participation under an IRB-approved protocol, with HIPAA-compliant de-identification of all associated clinical data.
How long does a prospective collection take to start?
Timelines depend on protocol complexity and cohort rarity. Feasibility review is the fastest step, followed by IRB submission and site or mobile-phlebotomy scheduling. Common cohorts move faster than rare-disease or narrow-inclusion studies.
Next step
Tell us the cohort you cannot find.
Send the inclusion criteria, sample types, and timepoints your study needs. We come back with a feasibility read on recruitability, volumes, and timeline — before any commitment.